Phase 2 Response Evaluation of Finite Systemic Therapy With Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART)
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Apalutamide (Primary) ; Degarelix (Primary) ; Leuprorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms RESTART
- 14 Jan 2021 Planned End Date changed from 30 Nov 2024 to 8 Jan 2021.
- 14 Jan 2021 Planned primary completion date changed from 30 Nov 2024 to 8 Jan 2021.
- 14 Jan 2021 Planned initiation date changed from 30 Nov 2020 to 24 Nov 2020.